全球血液疗法

GBT NASDAQ
54.24
+0.26
+0.48%
已收盘, 17:56 06/17 EDT
开盘
54.55
昨收
53.98
最高
56.04
最低
53.52
成交量
133.04万
成交均量(3M)
70.95万
52周最高
63.00
52周最低
30.15
换手率
2.36%
市值
30.59亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供全球血液疗法 GBT股票价格,全球血液疗法股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.
展开 >

最近浏览

名称
价格
涨跌幅